Interventions of Interest: During the public meeting, an independent appraisal committee voted unanimously (15-0) that the evidence was not adequate to demonstrate that aducanumab plus supportive care provides a net health benefit when compared to supportive care alone. In light of substantial uncertainty of patient benefit, policy recommendations call for: Date of Review: July 2021 For questions, please […]
Interventions of Interest: lanadelumab (Takhzyro™,Shire) C1 esterase inhibitors (Haegarda®, CSL Behring; Cinryze®, Shire) In 2018, ICER assessed the comparative clinical effectiveness and value of therapies for hereditary angioedema, a rare condition characterized by attacks of deep tissue swelling within the skin and/or mucosa. The cost-effectiveness and coverage considerations hinge on the frequency and intensity of attacks. […]
Interventions of interest: Congestive heart failure (CHF) describes the condition of fluid build-up in the body as the heart inefficiently fills with or pumps out blood. CHF results from other conditions that weaken the heart muscle including coronary artery disease, myocardial infarction, cardiomyopathy, and hypertension, and is a major public health concern. At the meeting, […]
Interventions of Interest: Tezacaftor/ivacaftor (SymdekoTM, Vertex Pharmaceuticals) Lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals) Ivacaftor (Kalydeco®, Vertex Pharmaceuticals) Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene. It is relatively rare, occurring in approximately 1 in 2,500 to 3,000 livebirths, but is the most common, lethal genetic disease in Caucasian populations. CF is […]
ICER assessed the comparative clinical effectiveness and economic value of digital health technologies (DHTs) for opioid use disorder. ICER has reviewed other related topics, such as abuse-deterrent opioid formulations, medication-assisted treatment for opioid use disorder, and non-drug interventions for lower back pain. The Midwest CEPAC determined current evidence is inadequate to demonstrate a net health […]
Interventions of Interest: nadofaragene firadenovec (Adstiladrin®, FKD Therapies Oy and FerGene) oportuzumab monatox (Vicineum®, Sesen Bio) Bladder cancer is the most common cancer involving the urinary system and usually presents with blood in the urine (hematuria). Overall, bladder cancer is the sixth most common cancer in the United States (US), with approximately 80,000 new cases […]
Treatments of Interest: Vedolizumab (Entyvio®, Takeda) Infliximab (Remicade®, Janssen) Infliximab-dyyb (Inflectra®, Pfizer) Infliximab-abda (Renflexis®, Merck) Adalimumab (Humira®, AbbVie) Golimumab (Simponi®, Janssen) Tofacitinib (Xeljanz®, Pfizer) Ustekinumab (Stelara®, Janssen) Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) that affects the mucosa, the innermost lining of the intestinal wall in the large bowel (i.e., the colon […]
Interventions of Interest: Tezacaftor/ivacaftor (SymdekoTM, Vertex Pharmaceuticals) Lumacaftor/ivacaftor (Orkambi®, Vertex Pharmaceuticals) Ivacaftor (Kalydeco®, Vertex Pharmaceuticals) Elexacaftor/tezacaftor/ivacaftor (Trikafta®, Vertex Pharmaceuticals) Cystic fibrosis is an autosomal recessive condition caused by mutations in the CFTR gene. It is relatively rare, occurring in approximately 1 in 2,500 to 3,000 livebirths, but is the most common, lethal genetic disease in […]